Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Employees

229

Sector

Biotechnology & Medical Research

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/01/26	8.570 $	+5.80%	1,156,888
09/01/26	8.100 $	-3.28%	1,176,286
08/01/26	8.375 $	-10.43%	1,639,342
07/01/26	9.350 $	+2.19%	1,359,974
06/01/26	9.150 $	+14.09%	1,269,982

Delayed Quote Nasdaq, January 12, 2026 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.570USD

Average target price

11.00USD

Spread / Average Target

+28.35%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 12/01/2026 GMT			5-day change	1st Jan Change
8.570 ^USD	+5.80%		+6.86%	+7.66%

01-12	Personalis, Inc. Announces Early Access Launch of Real-Time Variant Tracker	CI
01-08	Personalis Preliminary Q4 Revenue Within Analyst Range	MT

Capitalization	761M 652M 606M 565M 1.06B 68.59B 1.13B 6.98B 2.74B 32.82B 2.85B 2.8B 120B	P/E ratio 2025 *	-9.06x	P/E ratio 2026 *	-8.77x
Enterprise value	664M 568M 529M 493M 921M 59.82B 988M 6.09B 2.39B 28.62B 2.49B 2.44B 105B	EV / Sales 2025 *	9.66x	EV / Sales 2026 *	8.28x
Free-Float	67.32%	Yield 2025 *	-	Yield 2026 *	-

01-12	Personalis, Inc. Announces Early Access Launch of Real-Time Variant Tracker	CI
01-08	Personalis Preliminary Q4 Revenue Within Analyst Range	MT
01-08	Personalis reports select preliminary fourth quarter and full year 2025 results	RE
01-08	(PSNL) Personalis Expects Fiscal Q4 Revenue Range $17M to $18M, vs. FactSet Est of $17.6M	MT
12-17	Personalis announces new publication applying ultrasensitive ctDNA testing	RE
12-11	Personalis, Inc. Publishes Landmark Tracerx Lung Cancer Study in Cell, Demonstrating Ultrasensitive Ctdna Detection Months to Years Ahead of Imaging	CI
12-02	Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating	MT
11-25	Personalis says CMS revises reimbursement rate for Personal test for post-treatment surveillance of cancers	RE
11-10	Personalis Gets Medicare Coverage for Breast Cancer Recurrence Test; Shares Jump	MT
11-05	Personalis, Inc., Q3 2025 Earnings Call, Nov 04, 2025
11-04	Earnings Flash (PSNL) Personalis, Inc. Reports Q3 Revenue $14.5M, vs. FactSet Est of $13.3M	MT
11-04	Healthcare firm Personalis beats Q3 revenue estimates	RE
11-04	(PSNL) Personalis, Inc. Expects Q4 Revenue Range $15.7M - $20.7M	MT

12-02	Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating	MT
05/08/25	Healthcare firm Personalis' Q2 revenue misses estimates	RE
15/05/25	Guggenheim Initiates Personalis at Buy With $6 Price Target	MT
17/03/25	Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target	MT
16/08/24	BTIG Raises Personalis' Price Target to $7 From $5.50, Buy Rating Maintained	MT

Personalis, Inc. Share Price

Equities

PSNL

US71535D1063

Biotechnology & Medical Research

Valuation: Personalis, Inc.

Chart: Personalis, Inc.

Latest news: Personalis, Inc.

Last Transcript: Personalis, Inc.

Analysts' recommendations: Personalis, Inc.

Press Releases: Personalis, Inc.

News in other languages: Personalis, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Personalis, Inc.

ETFs: Personalis, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-12	Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™	BU
01-08	Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights	BU
12-17	Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors	BU
12-12	Personalis, Inc. - New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer	AQ
12-11	New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer	BU

03/02/23	Moderna : nouveaux essais cliniques de vaccins anticancéreux
27/04/22	Evaxion utilizará la plataforma ImmunoID NeXT® de Personalis para evaluar la eficacia de su terapia combinada para el tratamiento del melanoma avanzado
27/04/22	Evaxion nutzt ImmunoID NeXT Platform® von Personalis zur Untersuchung der Wirksamkeit einer Kombinationstherapie für Melanome in späten Stadien
26/04/22	Evaxion gebruikt het ImmunoID NeXT Platform® van Personalis om de werkzaamheid van combinatietherapie voor melanoom in een laat stadium te evalueren
26/04/22	Evaxion s’apprête à utiliser l’ImmunoID NeXT Platform® de Personalis pour évaluer l’efficacité d’une thérapie combinée contre le mélanome de stade avancé

1 day	+5.80%
1 week	+6.86%
Current month	+7.66%
1 month	-2.28%
3 months	+5.54%
6 months	+34.54%
Current year	+7.66%

1 week	7.87	9.74
1 month	7.68	9.74
Current year	7.72	9.74
1 year	2.83	11.4
3 years	0.89	11.4
5 years	0.89	53.46
10 years	0.89	53.46

Manager	Title	Age	Since
Christopher Hall CEO	Chief Executive Officer	57	01/03/2023
Aaron Tachibana CEO	Chief Executive Officer	65	30/12/2022
Richard Chen CTO	Chief Tech/Sci/R&D Officer	55	31/10/2011

Director	Title	Age	Since
Arthur Bowman BRD	Director/Board Member	79	30/04/2019
Karin Eastham CHM	Chairman	76	16/05/2022
Woodrow Myers BRD	Director/Board Member	72	05/03/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PERSONALIS, INC.	+5.80%	+6.86%	+53.31%	+210.51%	761M
LONZA GROUP AG	+0.05%	+5.64%	+3.93%	+16.01%	49.9B
IQVIA HOLDINGS INC.	-0.64%	+2.67%	+18.49%	+9.73%	41.02B
BEONE MEDICINES AG	-1.15%	+4.27%	+89.00%	+26.88%	36.96B
CELLTRION, INC.	+1.88%	+7.16%	+21.92%	+42.32%	31.91B
REVOLUTION MEDICINES, INC.	-1.24%	+49.59%	+180.45%	+292.00%	22.65B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-3.67%	+63.13%	+34,577.67%	+5,582.08%	21.81B
MEDPACE HOLDINGS, INC.	+0.71%	+2.11%	+70.78%	+165.23%	16.88B
EUROFINS SCIENTIFIC SE	+2.12%	+9.03%	+49.36%	+13.24%	14.8B
ICON PUBLIC LIMITED COMPANY	-0.68%	-8.82%	-17.45%	-19.09%	13.76B
Average	+0.95%	+13.58%	+3,504.75%	+633.89%	25.04B
Weighted average by Cap.	+0.25%	+12.71%	+3,054.41%	+538.22%

	2025 *	2026 *
Net sales	68.73M 58.86M 54.73M 51.03M 95.35M 6.19B 102M 631M 248M 2.96B 258M 252M 10.87B	83.54M 71.53M 66.52M 62.02M 116M 7.53B 124M 766M 301M 3.6B 313M 307M 13.21B
Net income	-83.44M -71.45M -66.45M -61.95M -116M -7.52B -124M -765M -301M -3.6B -313M -306M -13.19B	-86.65M -74.2M -69M -64.33M -120M -7.81B -129M -795M -312M -3.74B -325M -318M -13.7B
Net Debt	-97.34M -83.35M -77.52M -72.27M -135M -8.77B -145M -893M -351M -4.2B -365M -358M -15.39B	-69.5M -59.51M -55.34M -51.6M -96.41M -6.26B -103M -638M -251M -3B -261M -255M -10.99B